Abstract: Disclosed herein is a method for training a data-driven model for determining a user-selected parameter value related to the condition of a human including: (a) receiving an image of a body part of the human while the body part is illuminated by a light pattern containing at least one pattern feature, (b) determining skin pattern features from the image, where a skin pattern feature is a pattern feature which has been reflected by skin, (c) receiving from a user interface a user-selected parameter value related to the condition of the human, and (d) training a data-driven model with a training dataset comprising the skin pattern features and the user-selected parameter value.

Abstract: Disclosed herein is a method for determining an access right of a user to a requesting computer device, the method including, by an authenticating computer device: receiving (S1) a detector signal containing captured biometric information about the user from the requesting computer device, authenticating (S2) the user based on the detector signal, determining (S3) an access right information of the user based on the authentication and based on a prestored access right information indicating user rights associated with one or multiple users, the access right information indicating an extent to which the user is allowed to access the requesting computer device, and transmitting (S4) the access right information of the user to the requesting computer device.

Abstract: Disclosed herein is a method for characterizing material properties of an object, where the object has a form and including at least one material, the method includes receiving imaging data associated to the object, determining, by processing the received imaging data, at least one reflection feature corresponding to a spot in the first image: comparing, by processing the at least one reflection feature, the spot pattern comprised in the first image with reference spot patterns for obtaining a comparison result; and determining a material property of the object as a function of the comparison result. Further disclosed herein is a device with data processing capabilities and for implementing the method.

Abstract: The present invention relates to an isolated antibody which specifically binds human PDL1, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.

Abstract: The present invention relates to an isolated antibody which specifically binds human CD137, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid comprising a nucleotide sequence encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.

Abstract: The present invention relates to a multispecific antibody comprising at least one CD137 binding domain and at least one PDL1 binding domain, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid encoding said multispecific antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said multispecific antibody.

Abstract: The present invention relates to a multispecific antibody comprising one or two binding domains, which specifically bind to the extracellular domain of ROR1 (ROR1-BDs), and one binding domain, which specifically binds to CD3 (CD3-BD), wherein the multispecific antibody does not comprise an immunoglobulin Fc region. The present invention further relates to nucleic acids encoding said multispecific antibody, vector(s) comprising said nucleic acids, host cell(s) comprising said nucleic acids or said vector(s), and a method of producing said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said multispecific antibody and methods of use thereof.

Abstract: Disclosed herein is a method for authenticating a user for access involving at least a first device and a second device including: receiving an access request, in response to the access request, recording at least one image with the first device, extracting at least one facial feature of the at least one image, receiving a template from the second device, generating an access signal indicative of whether the user has access based on a comparison of the at least one facial feature and the template, and outputting the access signal.

Abstract: This invention relates to a hetero-dimeric multi-specific format of multiple antibody variable domains comprising a core of two split variable domain pairs wherein both variable light domains and the two cognate variable heavy domains are positioned in tandem on two separate protein chains, respectively, and wherein one of said variable domain pairs is specific for human serum albumin and the other said variable domain pair is specific for human CD3.

Abstract: The present invention relates to an isolated antibody which specifically binds human PDL 1, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.

Abstract: Disclosed herein is a method for authenticating a user for access to a vehicle, including: a. receiving an access request, b. in response to the access request, recording an image, c. extracting at least one facial feature of the image, d. receiving a template, e. generating an access signal indicative of whether the user has access based on a comparison of the at least one facial feature and the template, and f. outputting the access signal.

Abstract: The present invention relates to an antibody variable domain, which specifically binds to IL-31, to multispecific antibodies comprising one or two of said antibody variable domains and at least one further binding domain that specifically binds to a target different from IL-31. The present invention further relates to a nucleic acid or two nucleic acids encoding said antibody variable domain or said multispecific antibody, vector(s) comprising said nucleic acids or said nucleic acids, host cell(s) comprising said nucleic acid or said nucleic acids or said vector(s), and a method of producing said antibody variable domain or said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said antibody variable domain or said multispecific antibody and to methods of use thereof.

Abstract: The present invention relates to novel antibody variable domain combinations with advantageous properties.

Abstract: The present invention relates to a multispecific antibody comprising two antibody-based binding domains, which specifically binds to mesothelin (MSLN-BD); and at least one antibody-based binding domain, which specifically binds to CD3 (CD3-BD); wherein said multispecific antibody does not comprise an immunoglobulin Fc region polypeptide, and wherein each of said MSLN-BD binds to mesothelin (MSLN) with a monovalent dissociation constant (KD) in the range of from 0.5 to 20 nM, when measured by SPR. The present invention further relates to nucleic acid sequence(s) encoding said multispecific antibody, vector(s) comprising aid nucleic acid sequence(s), host cell(s) comprising said nucleic acid sequence(s) or said vector(s), and a method of producing said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said multispecific antibody and methods of use thereof.

Abstract: The present invention relates to a multispecific antibody comprising at least one CD137 binding domain and at least one PDL1 binding domain, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid encoding said multispecific antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said multispecific antibody.

Abstract: A metallic connection with a metal pipe, with a base body made of metal, with at least one supporting body made of metal and formed in one piece with the base body for insertion into a pipe end and with at least one pressing sleeve made of metal and connected to the base body for receiving the pipe end, the supporting body and the pressing sleeve being designed for radial pressing, the supporting body having a first sealing section arranged at the distal end with at least one radially encircling sealing tooth has a holding region adjoining the first sealing section in the axial direction, holding teeth which are distributed around the circumference and extend axially, and a second sealing section adjoining the holding region in the axial direction and having at least one radially extending sealing tooth.

Abstract: The present invention relates generally to an isolated antibody which specifically binds human CD137, and pharmaceutical compositions and methods of use thereof, a nucleic acid comprising a nucleotide sequence encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.

Abstract: The present invention relates to a multispecific antibody comprising at least one domain specifically binding to a tumor-associated immune checkpoint antigen with low affinity, and at least one domain specifically binding to a tumor-associated antigen (TAA), and pharmaceutical compositions and methods of use thereof.

Abstract: The present invention relates to novel antibodies that are specific for human CD3, in particular for the CD3? domain.

Abstract: The present invention relates to novel antibody variable domain combinations with advantageous properties.